Read More Here

FDA “Voice of the Patient” report: AUTISM

On May 4, 2017, FDA held a public meeting to hear perspectives from individuals with Autism, caregivers and other patient representatives on the most significant health effects and currently available therapies for autism. FDA conducted the meeting as part of the Agency’s Patient-Focused Drug Development initiative, an FDA commitment under the fifth authorization of the Prescription Drug User Fee Act (PDUFA V) to more systematically gather patients’ perspectives on their condition and available therapies to treat their condition. As part of this commitment, FDA held 24 public meetings between Fiscal Years 2013–2017, each focused on a specific disease area. The public meeting on Patient- Focused Drug Development for Autism was the 22nd public meeting of this commitment.

To View or Download full 25 page study: Voice of the Patient Autism just click here: Voice of Patient FDA